Structure Therapeutics Inc. American Depositary Shares (GPCR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Structure Therapeutics Inc. American Depositary Shares (GPCR) has a cash flow conversion efficiency ratio of -0.042x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-64.42 Million) by net assets ($1.52 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Structure Therapeutics Inc. American Depositary Shares - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Structure Therapeutics Inc. American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Structure Therapeutics Inc. American Dep debt and liabilities for a breakdown of total debt and financial obligations.
Structure Therapeutics Inc. American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Structure Therapeutics Inc. American Depositary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tianjin Guangyu Development Co Ltd
SHE:000537
|
0.106x |
|
Ebro Foods
MC:EBRO
|
0.106x |
|
Shanghai Huayi Group Corp Ltd A
SHG:600623
|
0.079x |
|
Dongfeng Motor Group Company Limited
F:D4D
|
-0.026x |
|
ROCKWOOL International A/S
CO:ROCK-A
|
0.059x |
|
China South Publishing & Media Group Co Ltd
SHG:601098
|
-0.021x |
|
Shaanxi Huaqin Technology Industry Co. Ltd. A
SHG:688281
|
N/A |
|
Brookfield Business Partners L.P.
TO:BBU-UN
|
0.085x |
Annual Cash Flow Conversion Efficiency for Structure Therapeutics Inc. American Depositary Shares (2020–2025)
The table below shows the annual cash flow conversion efficiency of Structure Therapeutics Inc. American Depositary Shares from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see Structure Therapeutics Inc. American Dep (GPCR) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.52 Billion | $-222.20 Million | -0.147x | -8.65% |
| 2024-12-31 | $864.84 Million | $-116.64 Million | -0.135x | +23.15% |
| 2023-12-31 | $452.97 Million | $-79.49 Million | -0.175x | -143.81% |
| 2022-12-31 | $-115.14 Million | $-46.12 Million | 0.401x | -19.37% |
| 2021-12-31 | $-64.73 Million | $-32.16 Million | 0.497x | -21.85% |
| 2020-12-31 | $-22.47 Million | $-14.28 Million | 0.636x | -- |
About Structure Therapeutics Inc. American Depositary Shares
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment… Read more